Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, Tae Won Yi, Samantha Hocking, Jessica Dawson, Smriti Raichand, Andrzej S. Januszewski, Meg Jardine
Topics & Concepts
MedicineHeart failureIntensive care medicineDiabetes mellitusAdverse effectClinical trialType 2 diabetesEmpagliflozinDiseaseHeart failure with preserved ejection fractionKidney diseaseEjection fractionInternal medicineEndocrinologyDiabetes Treatment and ManagementPancreatic function and diabetesPotassium and Related Disorders